For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

Novo Nordisk launched Ozempic in India on Friday—and the weight-loss drug will sell at a massive discount there, compared ...

Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...

Novo Nordisk A/S said its high-dose version of blockbuster Wegovy has been cleared by the European Union’s drug advisory board, opening the way for use of a shot that delivers more weight loss than ...

As Adam Fein of Drug Channels Institute puts it, these forces are finally puncturing the “ gross-to-net bubble ”—the vast gap ...

For 2026, the plan features significantly lower out-of-pocket costs for members who use the plan’s “narrow network” that ...

People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications.

Novo Nordisk's trial to treat Alzheimer's with its GLP-1 drug failed. The company has been losing market share to Eli Lilly. Novo Nordisk also lost a bidding war for a promising start-up. Novo Nordisk ...

A glimmer of hope for Alzheimer’s patients vanished Monday, when Novo Nordisk said a trial of an oral version of its weight loss drug Wegovy didn’t slow the progression of the disease in two large, ...

The latest round of Medicare price cuts affect 15 drugs, including Xtandi, an older prostate cancer drug from Pfizer and Astellas Pharma Inc. that will face a 48% discount off its 2024 list price. GSK ...

Novo Nordisk NOVO.B-1.06%decrease; red down pointing triangle filed for U.S. approval of a higher dose of its Wegovy weight-loss injection, with a decision expected within a month or two. The Danish ...